Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Prognostic Value of Baseline and Interim Positron Emission Tomography Markers in Diffuse Large B-cell Lymphoma Patients

Optimal PET parameters and imaging time points to prognosticate PFS as well as OS of patients with DLBCL have not been established.

Anti-PD-1 Antibodies as a Salvage Therapy for Patients With Diffuse Large B Cell Lymphoma Who Progressed/Relapsed After CART19/20 Therapy

In this study, investigators analyze data from five patients with R/R DLBCL who had disease progression or relapse following CART19/20 therapy and then treated with PD-1-blocking antibodies...

Journal of Hematology & Oncology
Novel Model Shows High Predictive Potential in Patients With DLBCL

A novel model that combines signatures of metabolic dysregulation with clinical features may aid in clinical decision-making among patients with DLBCL, according to research published in the Journa

Hematology Advisor

Polatuzumab Vedotin as a Salvage and Bridging Treatment in Relapsed or Refractory Large B-Cell Lymphomas

Pola is an effective treatment in heavily pretreated patients with r/r LBCL, but long-term remissions are rare.

Blood Advances
Impact of High-Dose Methotrexate on the Outcome of Patients With Diffuse Large B-Cell Lymphoma and Skeletal Involvement

Study investigators analyze the impact of adding high-dose methotrexate to standard chemotherapy on the outcome of patients with DLBCL and skeletal involvement.

Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma

Study investigators examine the relationship between PD-L2 expression and clinicopathological features in DLBCL.

Frontiers in Oncology
Whole Transcriptome Data Analysis Reveals Prognostic Signature Genes for Overall Survival Prediction in Diffuse Large B Cell Lymphoma

With the improvement of clinical treatment outcomes in DLBCL, the high rate of relapse in DLBCL patients is still an established barrier, as the therapeutic strategy selection based on...

Frontiers in Genetics
ctDNA and Early Relapse After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma

In a prospective study reported in the Journal of Clinical Oncology, investigators found that monitoring of ctDNA improved detection of early relapse after axicabtagene ciloleucel infusion in patie

The ASCO Post
Phase II Study of Naratuximab Emtansine Plus Rituximab in DLBCL

Adding the antibody-drug conjugate naratuximab emtansine to rituximab results in favorable OS and complete response rates for patients with R/R DLBCL, with a manageable safety profile.

The ASCO Post
The Regulation of miR-320a/XBP1 Axis Through LINC00963 for Endoplasmic Reticulum Stress and Autophagy in Diffuse Large B-Cell Lymphoma

This study incorporates fundamental research referring to considerable amounts of gene-sequencing data and bioinformatics tools to analyze the pathological mechanisms of DLBCL.

Cancer Cell International
Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study investigators aim to evaluate the antitumour activity and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL.

The Lancet Oncology
Value of Total Lesion Glycolysis and Cell-of-Origin Subtypes for Prognostic Stratification of Diffuse Large B-Cell Lymphoma Patients

This study aims to explore the added prognostic value of baseline metabolic volumetric parameters and cell of origin subtypes to the NCCN-IPI in nodal DLBCL patients.

Quantitative Imaging in Medicine and Surgery
Dynamic Changes in Peripheral Blood Lymphocyte Subset Counts and Functions in Patients With Diffuse Large B Cell Lymphoma During Chemotherapy

This study aims to analyze the lymphocyte subsets, their activities and their dynamic changes during immunochemotherapy in patients newly diagnosed with DLBCL.

Cancer Cell International
Ferroptosis-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients With Diffuse Large B-Cell Lymphoma

The aim of the current investigation is to perform a systematic study of ferroptosis and DLBCL prognosis to identify prognostic biomarkers in DLBCL.

Pharmacogenomics and Personalized Medicine
Loncastuximab Tesirine-lpyl for Heavily Pretreated Patients With Relapsed or Refractory DLBCL

The phase II LOTIS-2 trial has shown that the CD19-directed antibody–alkylating drug conjugate loncastuximab tesirine-lpyl produces durable responses in patients with R/R DLBCL.

The ASCO Post
Study of the Antilymphoma Activity of Pracinostat Reveals Different Sensitivities of DLBCL Cells to HDAC Inhibitors

DLBCL includes distinct molecular subsets or metabolically defined subtypes that rely in different ways on the B-cell receptor signaling pathway, oxidative phosphorylation, and glycolysis for...

Blood Advances
MicroRNA-383-5p Predicts Favorable Prognosis and Inhibits the Progression of Diffuse Large B-Cell Lymphoma

The present study aims to investigate the role of miR-383-5p in DLCBL. 

Oncology Letters
Optimal Timing and Criteria of Interim PET in DLBCL: A Comparative Study of 1692 Patients

The aim of this study is to determine the optimal timing and response criteria for evaluating prognosis with I-PET in DLBCL. 

Blood Advances
New CAR-T Approach Minimizes Resistance in B-Cell Lymphoma

Early results from a new CAR T-cell immunotherapy trial led by researchers find that using a bilateral attack instead of the conventional single-target approach helps minimize treatment resistance.

Oncology Times - Latest Articles
Infection-Related Morbidity and Mortality Among Older Patients With DLBCL Treated With Full- or Attenuated-Dose R-CHOP

Increased risk of infection-related hospital admission is independently associated with IDI >80% in older patients with DLBCL.

Blood Advances
Efficacy and Safety of Prophylactic High-Dose MTX in High-Risk DLBCL: A Treatment Intent–Based Analysis

In high-risk DLBCL patients, prophylactic HD-MTX does not improve CNS or survival outcomes but is associated with increased toxicities.

Blood Advances
CARs Are the Ride of the Future for Curing DLBCL

CAR T-cell therapy has the potential to cure the most diffuse large B-cell lymphoma patients who have recurrent disease.

Oncology Times - Latest Articles
Functional Characterization of PD1+TIM3+ Tumor-Infiltrating T Cells in DLBCL and Effects of PD1 or TIM3 Blockade

Activated B cell–like DLBCL shows increased levels of PD1+TIM3+ TILs with impaired functions.

Blood Advances
Establishment of a Typing Model for Diffuse Large B-Cell Lymphoma Based on B-Cell Receptor Repertoire Sequencing

The purpose of this study is to construct a new typing model for DLBCL patients based on the B-cell receptor and explore its potential molecular mechanism.

BMC Cancer
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

To explore the genetic mechanisms underlying treatment resistance in rrDLBCL and to identify candidate genes, study investigators perform targeted deep sequencing of 430 lymphoma-related genes...

Frontiers in Oncology
Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

The goal of this study is to compare lenalidomide plus R-CHOP (R2-CHOP) with placebo/R-CHOP in previously untreated, ABC-type DLBCL.

Journal of Clinical Oncology
Long-Term Outcomes of R-CEOP Show Curative Potential in Patients With DLBCL and a Contraindication to Anthracyclines

The R-CEOP regimen is a valid alternative to R-CHOP for patients with de novo DLBCL and an absolute contraindication to anthracyclines.

Blood Advances
A Rare Cause of Acute Liver Failure Due to Haemophagocytic Lymphohistiocytosis Secondary to Diffuse Large B-Cell Lymphoma

This is a case report of a 74-year-old man with acute liver failure secondary to haemophagocytic lymphohistiocytosis triggered by undiagnosed large B-cell lymphoma.

Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma

Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment has impacted the ability to enroll real-world patients in frontline trials of DLBCL.

Journal of Clinical Oncology
Identification of Super Enhancer-Associated Key Genes for Prognosis of Germinal Center B-cell Type Diffuse Large B-cell Lymphoma by Integrated Analysis

This study aims to explore the regulation of super enhancers on GCB-DLBCL by identifying specific SE-target gene.

GM-CSF Enhanced the Effect of CHOP and R-CHOP on Inhibiting Diffuse Large B-cell Lymphoma Progression via Influencing the Macrophage Polarization

In the present study, the combination use of CHOP and R-CHOP with GM-CSF is used to evaluate their effects on the tumor immune microenvironment of DLBCL.

Cancer Cell International
Identification and Validation of a Prognostic Gene Signature for Diffuse Large B-Cell Lymphoma Based on Tumor Microenvironment-Related Genes

Study investigators perform a systematic investigation of the TME and genetic factors associated with DLBCL to identify prognostic biomarkers for DLBCL.

Frontiers in Oncology
Distribution of Chimeric Antigen Receptor-Modified T Cells Against CD19 in B-Cell Malignancies

The unprecedented efficacy of CAR-T cell immunotherapy of CD19+ B-cell malignancies has opened a new and useful way for the treatment of malignant tumors.

BMC Cancer

source list reference